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In 1977, a woman with jaundice was told she had cancer of the head of the pancreas and was advised that she could not expect to live more than about 6 months. She began to take vitamin C, 10 grams daily. She was referred to me. I recommended she increase the vitamin C and I added a few other nutrients. Eventually she was taking 40 grams daily. Her CT scan 6 months later was negative, and she lived another 21 years. This patient's response triggered an increasing demand for a high-dose vitamin regimen from patients and later from the referring physicians. After a number of patients had been seen, I became curious as to whether or not this therapy was going to extend patients' life spans especially since Cameron and Pauling 2 reported a significant increase in survival compared with a control group in a study of high-dose vitamin C. I did not doubt that the regimen improved quality of life, as vitamins have done for so many patients.
After I had seen about 40 patients, I became aware that my cancer patients who followed the program lived longer compared with those who did not. I did not have a proper comparison group and decided that the best I could do would be to use all patients who did not stick to the program for at least 2 months as controls and to use all patients who were on the program at least 2 months as the treatment group. This is not a satisfactory control but was the only one that I could use: as a solo practitioner, it was not possible for me to plan and carry out a prospective randomized placebocontrolled study. I should make it clear that I did not treat the cancer in these patients. That was left to the physicians, surgeons, oncologists, radiologists, and cancer specialists who were responsible for diagnosis and treatment.
Eventually I published the results of this work. 3, 4 In these reports, I discussed the methods used, the type of patients, and the results. In my series, the results were superior for patients on the program compared with patients who were in the control group. My observations did not prove that adding vitamins was helpful, but they did make that conclusion more plausible. 5 My patients were pleased. After I had seen well over 1000 patients, I suggested to Professor Harold Foster that the data I had should be looked at to see if my conclusions were valid by comparing my patients with other patients not given vitamin therapy. I thought I had a small mine of relevant clinical information since the charts were very complete and contained data from the cancer clinic, from the referring physicians, and from my own follow-up notes. I hoped that this would challenge others to run careful randomized controlled experiments to which my data did not lend itself. This suggestion led to the study by Lesperance et al. 1 I hoped that the results of this investigation, either positive or negative, would lead to valuable information about the parameters of vitamin treatment, not that it would lead to controversy. I was naive in this hope, for which I blame the experience I had many years ago when I was research biochemist at a flour mill making thousands of tons of flour daily. Adding thiamine to flour had been mandated, and there was no good laboratory test that would tell the miller whether these standards were being matched. The official association of cereal chemists appointed a committee to examine the reasons why different laboratories were obtaining results that differed by as much as 100%. Rather than initiate a debate or battle between laboratories, it appointed a series of small committees each of which undertook to examine one aspect of the test. Within a remarkably short time, the test was improved so much that the experimental errors between laboratories were reduced to tolerable levels. This fine example of scientific cooperation has always remained with me. I am being disillusioned very quickly. I made available all of my nearly 270 breast cancer patients with their consent, but only about one third were selected based on the prognosis. Women with unilateral disease and no metastases were selected. The remainder of my patients in the series, who were not selected for matching, were stages 2, 3, and 4. I was surprised at this selection as I had expected that a sample of my total group would have been used, but I was not on the selection team. The selected patients were matched, and the outcome of treatment using survival data was examined.
There was no significant statistical difference. We, all the authors as a group, concluded that "Overall survival was similar for the two groups (log-rank test, p = 0.36)." This means that survival of the treated group was not worse and no better and that the addition of vitamins did not increase the death rate.
I had the impression, based on the survival records of my extensive series combined with the observations by Cameron and Pauling 2 showing that some patients on vitamin C lived longer than controls, that the patients in this study would also live longer. But the reasons for this were not clear. This study provides moderately good evidence but does not prove that vitamin therapy is not likely to prevent recurrence in patients with early stage breast cancer.
Scientifically the next step is to examine the methods used in both these studies to see why there was this divergence in conclusions. It does not mean that the use of vitamins was of no value, because this one study has to be considered in view of the previous studies that show that the use of vitamins was beneficial. There is no doubt that the use of foods rich in antioxidants is beneficial, and it would be highly implausible to find that adding more of these antioxidants could be harmful. Yet one of the coauthors released information to the media, contrary to his conclusion in the paper, stating that the addition of vitamin C was damaging. This was given major headlines in the press, which has no inclination or desire to enter into any accurate controversy in debate but merely to generate headline news that will create public attention.
Since then I have thought about what might have been the reasons for this discrepancy. Some reasons are as follows: 1. In my series, all the patients had come to see me, whereas in the control series none had been seen at my clinic. But to see me, these patients had to be referred, and to be referred they had to be highly motivated. There was so much antagonism to the use of vitamins when I started that some patients had to use heroic measures before they could obtain a referral. They were highly motivated because they had been told that there was no further treatment and that they were terminal. Over the past 10 years, the resistance has not been as severe and earlier stage patients have been coming. Does this mean that patients with higher motivation would be more apt to follow the high-dose vitamin program? Had my total group been tested instead of excluding the sickest group this might have been answered. Do late-stage breast cancer cases do better because they are more highly motivated? 2. This study illustrates a problem inherent in clinical trial design. It was not possible to do randomized, prospective placebo-controlled trials. My original observation used what I have called a pseudo control, and the present study used a case-by-case control comparison group. Neither is really acceptable. I was aware of this, since under my direction the very first double-blind controlled experiments ever in psychiatry were conducted, when between 1951 and 1960 we tested the effect of niacin, niacinamide, and placebo in the treatment of acute schizophrenia patientswith positive results. Although I know the method, I was, of course, not able to use it as a single practitioner in private practice. 3. It is possible that my patients were not given enough vitamin C or else did not follow the full program. I saw them only twice at the onset of their illness unless they were very depressed and could not monitor what they were doing, and thus they returned several years after I first saw them. Many patients, when they relapsed and came back told me that they had been so well they were no longer taking any of the vitamins. The protective effect of antioxidants could not extend long once the antioxidants were no longer being taken.
The positive results obtained by Cameron and Pauling 2 were discounted as not proving any benefit by critics who said that the only way to test the treatment is by randomized controlled trials. Hoffer 4 points out, however, that this is not yet a valid approach because although there is reason to suspect that nutritional therapy can modify the course of some cancers, it is not clear what mechanism is involved or which patients will respond to which specific regimen. The Mayo clinic trials of vitamin C (see Cameron and Pauling 2 ) show that it is a mistake to prematurely carry out randomized clinical trials until these parameters can be established.
But to conclude that vitamin C is dangerous because it is an antioxidant is totally wrong. Moss, in his book on antioxidants, 6 points out that every paper published shows that antioxidant therapy is not dangerous. He points out that oncologists routinely use non-vitamin C antioxidants as part of their treatment and that these non-vitamin C antioxidants have been tested and have not interfered with chemotherapy. 7, 8 Many oncologists believe that vitamin C interferes with chemotherapy, but their views are based entirely on speculation while ignoring the literature already published. They are not opposed to antioxidants. They are opposed to vitamins as antioxidants.
